MX2022004678A - Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. - Google Patents
Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MX2022004678A MX2022004678A MX2022004678A MX2022004678A MX2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A MX 2022004678 A MX2022004678 A MX 2022004678A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- beta
- treating alzheimer
- amyloid antibody
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924633P | 2019-10-22 | 2019-10-22 | |
| PCT/US2020/056676 WO2021081101A1 (en) | 2019-10-22 | 2020-10-21 | Anti-beta-amyloid antibody for treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022004678A true MX2022004678A (es) | 2022-08-15 |
Family
ID=73344157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022004678A MX2022004678A (es) | 2019-10-22 | 2020-10-21 | Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220372123A1 (https=) |
| EP (1) | EP4048695A1 (https=) |
| JP (2) | JP2022553329A (https=) |
| KR (1) | KR20220084095A (https=) |
| CN (1) | CN114599393A (https=) |
| AU (1) | AU2020371612A1 (https=) |
| BR (1) | BR112022007595A2 (https=) |
| CA (1) | CA3158513A1 (https=) |
| CO (1) | CO2022004902A2 (https=) |
| IL (1) | IL292363A (https=) |
| JO (1) | JOP20220092A1 (https=) |
| MX (1) | MX2022004678A (https=) |
| WO (1) | WO2021081101A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2019152706A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a6a antibodies and methods of use thereof |
| US11472874B2 (en) | 2018-01-31 | 2022-10-18 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| TW202300517A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| TW202300518A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗N3pGlu類澱粉β抗體及其用途 |
| WO2023081194A2 (en) * | 2021-11-03 | 2023-05-11 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
| AU2022439338A1 (en) * | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| WO2024086796A1 (en) * | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| US20240207362A1 (en) * | 2022-10-25 | 2024-06-27 | Institute For Basic Science (Ibs) | Extracranial Methods For Facilitating Cerebrospinal Fluid Drainage |
| EP4455161A1 (en) | 2023-04-24 | 2024-10-30 | ONO Pharmaceutical Co., Ltd. | Human-derived anti-collapsin response mediator protein 2 (crmp2) antibodies |
| TW202530246A (zh) | 2023-09-15 | 2025-08-01 | 愛爾蘭商歐賽爾普羅希那有限公司 | 細胞穿透劑及其用途 |
| WO2025117721A1 (en) * | 2023-11-27 | 2025-06-05 | Massachusetts Institute Of Technology | Reconstituted lipoprotein particles to rescue lipid defects in the alzheimer's brain |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008081008A1 (en) | 2007-01-05 | 2008-07-10 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
| WO2008141321A1 (en) * | 2007-05-14 | 2008-11-20 | Medtronic, Inc. | Methods and device to neutralize soluble toxic agents in the brain |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| EP2598882B1 (en) * | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
| ME03008B (me) * | 2011-09-19 | 2018-10-20 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti |
| US20150315267A1 (en) * | 2012-12-07 | 2015-11-05 | Thierry Bussiere | A method of reducing brain amyloid plaques using anti-ab antibodies |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN114796481A (zh) * | 2016-06-07 | 2022-07-29 | 生物基因国际神经科学有限责任公司 | 治疗阿尔茨海默病的方法 |
-
2020
- 2020-10-21 KR KR1020227015913A patent/KR20220084095A/ko active Pending
- 2020-10-21 AU AU2020371612A patent/AU2020371612A1/en active Pending
- 2020-10-21 US US17/770,997 patent/US20220372123A1/en active Pending
- 2020-10-21 CA CA3158513A patent/CA3158513A1/en active Pending
- 2020-10-21 CN CN202080073830.0A patent/CN114599393A/zh active Pending
- 2020-10-21 IL IL292363A patent/IL292363A/en unknown
- 2020-10-21 EP EP20804740.7A patent/EP4048695A1/en active Pending
- 2020-10-21 JP JP2022523595A patent/JP2022553329A/ja active Pending
- 2020-10-21 BR BR112022007595A patent/BR112022007595A2/pt unknown
- 2020-10-21 MX MX2022004678A patent/MX2022004678A/es unknown
- 2020-10-21 WO PCT/US2020/056676 patent/WO2021081101A1/en not_active Ceased
-
2022
- 2022-04-19 CO CONC2022/0004902A patent/CO2022004902A2/es unknown
- 2022-04-20 JO JOP/2022/0092A patent/JOP20220092A1/ar unknown
-
2025
- 2025-10-27 JP JP2025181171A patent/JP2026012271A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021081101A1 (en) | 2021-04-29 |
| IL292363A (en) | 2022-06-01 |
| AU2020371612A1 (en) | 2022-05-19 |
| CA3158513A1 (en) | 2021-04-29 |
| JP2026012271A (ja) | 2026-01-23 |
| CO2022004902A2 (es) | 2022-07-08 |
| BR112022007595A2 (pt) | 2022-08-23 |
| KR20220084095A (ko) | 2022-06-21 |
| JOP20220092A1 (ar) | 2023-01-30 |
| CN114599393A (zh) | 2022-06-07 |
| EP4048695A1 (en) | 2022-08-31 |
| US20220372123A1 (en) | 2022-11-24 |
| JP2022553329A (ja) | 2022-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022004678A (es) | Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer. | |
| CO2019011349A2 (es) | Anticuerpos anti-péptido beta amiloide n3pglu y sus usos | |
| ZA202107358B (en) | Method for treating alzheimer's disease | |
| CL2021003132A1 (es) | Anticuerpos que se unen a cd3 (divisional de solicitud n° 202101506) | |
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| MX2021011489A (es) | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX2018015022A (es) | Métodos para el tratamiento de la enfermedad de alzheimer. | |
| MX2020009856A (es) | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). | |
| ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| MX2024006689A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| EA201892190A1 (ru) | Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы | |
| AR119158A1 (es) | Tratamientos de angioedema hereditario | |
| BR112021011729A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
| CL2021001389A1 (es) | Formulaciones en cápsula | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| AR119159A1 (es) | Tratamientos de angioedema | |
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| CO2018013828A2 (es) | Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato |